Autosomal dominant polycystic kidney disease: updated perspectives.
Rastogi A, Ameen KM, Al-Baghdadi M, Shaffer K, Nobakht N, Kamgar M, Lerma EV.
Ther Clin Risk Manag · review-article; review; journal article · DOI 10.2147/tcrm.s196244 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tesevatinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
11 träffarA safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic BI, Wakelee HA.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-018-3646-0Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.
Sweeney WE, Frost P, Avner ED.
World J Nephrol · research-article; journal article · DOI 10.5527/wjn.v6.i4.188Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Yu HA, Riely GJ.
J Natl Compr Canc Netw · research-article; journal article · DOI 10.6004/jnccn.2013.0024Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA.
J Thorac Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1097/jto.0b013e31824c943fEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W.
J Thorac Oncol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/jto.0b013e31823c5aeeXL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Pietanza MC, Lynch TJ, Lara PN, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA.
J Thorac Oncol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1097/jto.0b013e31822eebf9Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Pakkala S, Ramalingam SS.
Clin Lung Cancer · review; journal article · DOI 10.3816/clc.2009.s.003Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ.
J Thorac Oncol · review; journal article · DOI 10.1097/jto.0b013e318174e96eEXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T, Boukouvala S, Calkins K, Cutler RE, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-07-4367Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-06-2590